Canada: Screening Secondary Market Liability Actions: The Supreme Court Raises The Bar For Plaintiffs

On April 17, 2015, the Supreme Court of Canada (SCC) rendered its opinion in Theratechnologies inc. v. 121851 Canada inc., 2015 SCC 18 (Theratechnologies), its first decision on the Quebec statutory secondary market liability regime adopted in 2007 pursuant to a reform of the Quebec Securities Act (QSA).  Like its sister statutes in other provinces, although the QSA regime facilitates a plaintiff's burden, mostly by presuming that variation in market price is linked to a misinformation or omission, it also imposes an authorization process under which a claimant must establish that its action is brought in good faith and has a reasonable possibility of success.

Adopting a similar approach as the Quebec Court of Appeal, the SCC clarified the test applicable to the authorization of claims pursuant to the QSA by comparing it to the less stringent test applicable to authorization of a class actions in Quebec and by specifying the evidence and the analysis of the evidence to be performed by the court seized with an authorization motion under the QSA.

In contrast with the Quebec Court of Appeal1, however, which had authorized the class action claim pursuant to s. 225.4 QSA by the shareholders of Theratechnologies Canada Inc. (Thera), a public company listed on the Toronto Stock Exchange, the SCC reversed on the result and held that the evidence brought forward by the plaintiffs shareholders did not establish a reasonable possibility that the action could succeed.

More precisely, the SCC held that queries made by a regulator, the U.S. Food and Drug Administration (FDA) in this case, during the authorization process of a drug were not material if the issues raised by the regulator had been previously mentioned in public disclosures of the issuer.  In this respect, the SCC commented on the expected knowledge of a reasonable investor and concluded that if previous public disclosures made by an issuer addressed certain issues and specified that they were not significant, a reasonable investor should have known that the questions raised by the regulators regarding the same issues were not material.

In doing so, the SCC ruled on whether a material change had occurred, whereas the lower courts had decided that this question should be left for the merits stage.  As a result, the SCC confirmed that the analyses of judges deciding motions to pursue secondary market liability claims under the QSA and similar statutes may have to be comprehensive enough to determine whether or not a material change occurred.


Thera develops and markets therapeutic products. Under the QSA, Thera is a reporting issuer which must comply with continuous disclosure obligations. As such, in the event of any non-public material change that would reasonably be expected to have a significant effect on the market price or value of its securities, Thera is obliged to issue a news release disclosing the nature and the substance of this change.

In 2009, Thera filed an application with the FDA for approval of a major drug called Tesamoreline. The ensuing approval process took place in 2009 and 2010 and involved the FDA questioning Thera on the product, including asking about the risks of side effects of the drug. Thera did not disclose to the public the specific questions posed by the FDA, which included queries about the risks of diabetes and cardiovascular diseases. Nor did Thera respond directly to the FDA questions.

The ultimate step of the FDA approval process is a public hearing where all interested parties can be heard. May 27, 2010 was selected by the FDA as the date for the hearing. In accordance with FDA practice, on May 25, 2010, i.e. two days prior to the hearing, the FDA published information compiled at that time in the approval process, including its questions related to the possible side effects of Tesamoreline.

Although Thera did not react to the publication, the information released by the FDA caught the attention of financial analytics companies Bloomberg, Dow Jones, Thomson, and Reuters, which issued news releases about potential risks based on their reading of the questions posed by the FDA. The market reacted intensely to the news releases by the financial analytics companies; Thera's stock was heavily traded that day and lost 58% of its value. Thera's stock was the object of a cease trading order on May 27. When trading resumed on May 28, and after Thera confirmed that the FDA had approved Tesamoreline as a new drug, the stock regained its value.

The claimant, 121851 Canada Inc. (121Can), sold its stock at a loss on May 25. In a motion for authorization to pursue a secondary market liability claim under s. 225.4 QSA and to institute a class action filed a few months later, 121 Can alleged a failure on the part of Thera to disclose on a timely basis a material change, i.e. the questions raised by the FDA during the drug approval process.

Lower Courts' Decisions

  1. Applicable Test for Authorization

On February 24, 2012, the Quebec Superior Court authorized 121Can's secondary market liability claim under the QSA.

Although mostly in agreement with the Court below, the Court of Appeal found it necessary to "attenuate" some of the statements made by the Superior Court.  In particular, it was of the opinion that the authorization process under the QSA imposes a burden of proof, rather than a mere burden of "demonstration" as suggested by the Superior Court.  As a result, the Court of Appeal specified that a claimant under the QSA must present sufficient evidence to establish a reasonable possibility of success, despite the fact that such evidence may vary according to the circumstances.

The Court of Appeal acknowledged that the "reasonable possibility" that a secondary market liability claim will be resolved in favour of the plaintiff under the QSA is more stringent than the class action "colour of right" filtration mechanism of art. 1003 CCP ("the facts alleged seemed to justify the conclusions sought").  However, the Court insisted that a possibility of success is not tantamount to a probability or preponderance of proof.  The burden is therefore situated between the simple burden of proving "colour of right" and the more onerous balance of probabilities.

The Court of Appeal described the criterion of a reasonable possibility of success as being more than just an obstacle to frivolous and meritless actions.  The QSA filtration mechanism involves a summary appreciation of the alleged right of action to avoid claims with no reasonable chance of success without transforming it into a trial on the merits.  The Court cautioned against conceiving the QSA authorization process as a "mini-trial" prior to the institution of the action.

Because Ontario and British Columbia have enacted provisions similar to s. 225.4 QSA, the Court of Appeal relied on cases from those jurisdictions in order to determine the applicable test for authorization. However, the Court mentioned that restraint must be applied when considering the "particularly thorough analyses" conducted in some of the Ontario decisions prior to deciding on authorization (see paras. 125-126). The Court stressed that unlike the QSA and CCP, the Ontario Securities Act and class action certification process contemplate the filing of detailed affidavits and the examination of affiants.

Nevertheless, the Court stated that the authorization judge must ensure that a secondary market liability claim is "supported by real and tangible evidence", which can take the form of sworn statements, examinations and properly filed exhibits (see paras. 129-31).

  1. Claim Filed Against Thera

Although 121Can had chosen not to file any sworn statements, the Court of Appeal mentioned that the authorization hearing proceeded on the basis that the exhibits relied upon on both sides (almost 40) were admitted and appropriately filed. The Court also stressed that Thera had filed two sworn statements and the examination before plea of 121Can's representative.

The Court agreed with the Superior Court that 121Can had demonstrated a reasonable possibility of success for its claim through a well-developed theory of the case (which should be analyzed at the authorization stage). 121Can's theory was supported by numerous exhibits and by the explanations provided by the representative of 121Can during its examination by Thera.  The Court stressed that 121Can's claim identified a precise event that it alleged should have been disclosed, i.e. the questions raised by the FDA concerning the possible side effects of Tesamoreline. The Court of Appeal confirmed that the lower court was correct in not determining at this stage whether the queries from the FDA could amount to a material change. According to the Court, such a determination must be reserved for the merits.

SCC's Decision (Reasons by Abella J.; McLachlin, C.J., Rothstein, Cromwell, Moldaver, Karakatsanis and Wagner JJ. concurring)

  1. Applicable Test for Authorization

The SCC acknowledged that the objective of the regime set out in s. 225.4 QSA is to filter actions to those brought in good faith and which show a "reasonable possibility" of being resolved "in favour of the plaintiff".  The regime, as the SCC noted, reflects an attempt to strike a balance "between preventing unmeritorious litigation and strike suits and, at the same time, ensuring that investors have a meaningful remedy when issuers breach disclosure obligations".

In line with the Quebec Court of Appeal, the SCC acknowledged that the "reasonable possibility" of success required under s. 225.4 QSA sets out a different and higher standard than the general threshold for authorization of a class action under the CCP (see paras. 35 and 36).  This higher threshold requires sufficient evidence to persuade the court that there is a realistic chance that the action will be resolved in favour of the claimant, thus the claimant is required to offer "some credible evidence" in support of its claim.  However, the authorization stage is not a trial and the regime aims at preventing costly strike suits and litigation with no or little chance of success.  As a result, courts must undertake a reasoned consideration of the evidence in order to ensure that the action has some merit, but should not perform a full analysis of the evidence (see para. 39).

The SCC also acknowledged that lower courts, including in Ontario and British Columbia, had struggled to find the proper balance between applying a simple screening of plainly unmeritorious "strike suits" or, as Justice Belobaba put it in Ironworkers Ontario Pension Fund (Trustee of) v. Manulife Financial Corp. (2013), 44 C.P.C. (7th) 80 (Ont. S.C.J.), applying "a preliminary merits test that should have more bite" (para. 37).  Although the SCC did not expressly endorse the latter test proposed by Justice Belobaba, the Court's subsequent analysis of the claim of 121Can and its view "the threshold should be more than a "speed bump"" (para. 38) arguably espouse a very similar test.

  1. Claim Filed Against Thera

Unlike the Court of Appeal, the SCC pushed the analysis of the evidence further and found that in this case 121Can had not met its burden of proof in that it had not provided any evidence of a material change in Thera's operations, capital or business that could have triggered timely disclosure obligations.

Although it did not specifically say so, the SCC rejected the Quebec Court of Appeal's view that the determination of whether the questions raised by the FDA concerning the possible side effects of Tesamoreline amounted to a material stage had to be reserved for the merits.

The SCC concluded that the FDA briefing materials, including the FDA's question respecting glucose intolerance and development of diabetes, did not constitute a material change for two reasons: first, these side effects had already been disclosed in the results of the clinical trial and second, there is no evidence that the fact that the FDA was asking these question was not part of its regular and routine process.

The SCC ruled that the side effects are not, in themselves, a material change merely because Thera had previously disclosed that it was monitoring some of them closely, particularly blood sugar and diabetes.  In addition, the clinical studies explicitly found that these side effects were not significant.  As a result, a "reasonable investor who read Thera's news releases would have known" that these side effects existed and were not material.

In addition, the SCC held that the fact that the FDA had asked these questions is not a material change.  In doing so, the SCC provided its interpretation of the Canadian Securities Administrators (CSA)'s National Policy 51-201 – Disclosure Standards (NP 51-201).  The SCC rejected 121Can's view that because NP 51-201 includes, among its list of potentially "material" information, "any development that affects the company's resources, technology, products or markets", the market's reaction demonstrated that the FDA's concerns about side effects constituted a material change.  The SCC reiterated the difference between material facts and material change and refused to accept this interpretation of NP 51-201, notably noting that it would expand the statutory obligations of timely disclosure beyond what the Quebec legislator had intended.

The SCC analogized the FDA preoccupations in this case to the intra-quarterly results in Kerr v. Danier Leather Inc., [2007] 3 S.C.R. 331, which the Court found "did not constitute a material change to the business, operations or capital of the company because the warm weather that triggered the drop in sales was external to the company and its business" (para. 50).

Finally, the Court questioned the utility that a press release by Thera about the FDA preoccupations would have had and cautioned against the "risks of excessive disclosure" which can "simply ... bury the shareholders in an avalanche of trivial information — a result that is hardly conducive to informed decision making" (para. 55, internal references omitted).

Conclusion and Comments

Public issuers and class action defence lawyers will certainly welcome the SCC's decision and its interpretation of the disclosure requirements, as well as its comments about the expected knowledge of reasonable investors.

Although it agreed with the Quebec Court of Appeal that the QSA filtration mechanism should not be transformed into a mini trial on the merits, the SCC disagreed that determining whether the queries from the FDA could amount to a material change crossed into the merits territory.  As such, Justice Belobaba's words of "a preliminary merits test that should have more bite" may aptly describe the test applied by the SCC in this case.

More broadly, the decision can be viewed as another effort on the part of the SCC to promote procedural tools which can lead to preliminary dismissal of actions, in continuation with its earlier decisions in Hryniak v. Mauldin, 2014 SCC 7, and Attorney General of Canada v. Confédération des syndicats nationaux, 2014 SCC 49.

The SCC does not provide guidance as to the role of evidence where the authorization process under the QSA coincides with that applicable to class actions in Quebec. Evidence is required under the former regime, while severely restricted under the latter.  Given overlapping substantive issues in both authorization processes, Quebec courts may have to establish guidelines as to how evidence is submitted and considered in this new context.

Application to the Common Law

On February 12, 2015, the Supreme Court of Canada heard the appeals arising from a trilogy of securities class action cases, Green v. CIBC, Silver v. IMAX and Celestica v. Millwright Regional Council of Ontario Pension Trust Fund.  While the main issue to be addressed relates to the application of the limitation period in the context of the Ontario Securities Act and the Class Proceedings Act (for a summary of the issues, please refer to our post here:, the standard of the test for leave as set out in the Securities Acts of the common law provinces remains unsettled.

Theratechnologies may offer some insight to practitioners and market participants alike who are anxiously awaiting guidance from the Court on the proper interpretation of the leave test.

Case Information

Theratechnologies inc. v. 121851 Canada inc., 2015 SCC 18

Docket:  35550

Date of Decision: April 17, 2015


1. 2013 QCCA 1256. For an analysis of and comments on the Quebec Court of Appeal decision, see our earlier post at

To view the original article please click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.